← All trials
NCT00922480
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2008
- Primary completion
- Jul 1, 2009
- Completion date
- Sep 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 506
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- University of UlsanCollaborator
- Inha UniversityCollaborator
- Seoul National UniversityOverall official - principal investigator
- Kangbuk Samsung HospitalCollaborator
- Korea UniversityCollaborator
- Ajou UniversityCollaborator
- Yonsei UniversityCollaborator
- Hanyang UniversityCollaborator
- Catholic University of KoreaCollaborator
- Konkuk UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Keimyung UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Chungnam National UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Dongguk UniversityCollaborator
- Konyang UniversityCollaborator
- Yeungnam UniversityCollaborator
- Seoul National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.